Exome sequencing can misread high variant allele fraction of somatic variants in UBA1 as hemizygous in VEXAS syndrome: a case report

Matheus V. M. B. Wilke1, Eva Morava-Kozicz2,3*, Matthew J. Koster4, Christopher T. Schmitz1,3, Shannon Kaye Foster5, Mrinal Patnaik6, Kenneth J. Warrington4, Eric W. Klee1,2,7 and Filippo Pinto e Vairo1,2

Abstract

Background: VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) is a recently described syndrome caused by a somatic missense variant at the methionine-41 (p.(Met41)) position in the ubiquitin-like modifier activating enzyme 1 (UBA1) in Xp11.3. Germline pathogenic variants in UBA1 are associated with a distinct phenotype: a syndrome with severe neurologic features associated with loss of anterior horn cells and infantile death denominated X-Linked Spinal Muscular Atrophy 2 (SMAX2) (OMIM 301,830).

Case presentation: We report a male individual with the phenotype of VEXAS syndrome that was initially identified through exome sequencing (ES) as having a hemizygous germline variant in UBA1 due to high variant allele frequency (VAF). Research Sanger sequencing was able to confirm the absence of the p.(Met41Val) variant in a skin biopsy and in gastric mucosa tissue sample confirming the variant happened as a postzygotic event.

Conclusions: The present case exemplifies the diagnostic challenge that was imposed by the high VAF detected by ES that failed to correctly demonstrate that the variant was in a mosaic state. Sequencing of different tissues should be considered when there is conflict between the UBA1 variant status and the clinical findings.

Keywords: VEXAS syndrome, Variant allele frequency, X-Linked spinal muscular atrophy 2, Case report

Key message

- Exome sequencing can misread high variant allele fraction in UBA1 as hemizygous in VEXAS syndrome.
found in somatic cells and affects predominantly males, with only 4 female cases reported, all related to monosomy X [3–7]. The main symptoms of VEXAS syndrome include rheumatologic manifestations such as arthralgias, ear and nose chondritis, recurrent fevers, dermatologic conditions, and pulmonary inflammatory manifestations [3–5].

Germline pathogenic variants in \textit{UBA1} are associated with a distinct phenotype: a syndrome with severe rheumatologic features associated with loss of anterior horn cells and infantile death denominated X-Linked Spinal Muscular Atrophy 2 (SMAX2) (OMIM 301,830).

We report on an individual with the phenotype of VEXAS syndrome initially suspected as having an apparent hemizygous germline variant in \textit{UBA1} due to high variant allele frequency (VAF) in a clinical exome sequencing (ES).

Case presentation
A 46-year-old previously healthy male presented with priapism, chronic recurrent fevers, and elevated inflammatory markers treated with intermittent glucocorticoids. There was no other significant family history of autoimmune disorders or similar symptoms.

At the age of 55 years, he developed bilateral episcleritis and testicular pain. Two skin nodule biopsies were obtained, one showed panniculitis (Fig. 1A) and the other medium-vessel vasculitis. His laboratory findings included positive antinuclear antibody (ANA), positive anti-Ro (SS-A) and markedly elevated IL-2R (Table 1).

The patient was clinically suspected to have polyarteritis nodosa (PAN) due to the presence of medium vessel vasculitis, reported in a skin biopsy, associated with testicular pain and swelling, or cryopyrin-associated periodic syndrome (CAPS). A multi-gene panel was performed with no pathogenic variants identified in 73 genes associated with monogenic autoimmune diseases.

The patient received chronic prednisone (average dosage 20 mg/day) to control inflammatory symptoms. Adverse effects of long-term use of glucocorticoids included type 2 diabetes and cataracts noted around the age of 60 years. He also developed symmetric bilateral high-tone sensorineural hearing loss, which at the time was presumed due to use of Amikacin to treat chronic, recurrent disseminated \textit{Mycobacterium chelonae}. Sequential trials of different medications were unable to successfully control the symptoms or allow successful glucocorticoid tapering (Additional file 1: Table S1). He was trialed on intravenous immunoglobulin therapy by the age of 60 which helped increase his blood counts and ameliorate symptoms.

Three bone marrow (BM) biopsies were performed between age 59 and 61 years. All three samples showed marked hypercellularity (highest 90%), with decreased erythropoiesis, increased granulopoiesis with mild cytologic atypia, and moderately decreased megakaryopoiesis. Cytoplasmic vacuolization was observed in both erythroid and myeloid precursors.

At 62 years of age, the patient was referred to the Department of Clinical Genomics because of ongoing undiagnosed autoinflammatory symptoms. After comprehensive genetic investigation, including ES, the patient remained undiagnosed. He died at age 63 due to sepsis without a unifying diagnosis.

Two years after initial ES and one year after the patient’s death, the clinical genetic laboratory issued a revised report noting a hemizygous (NM_003334.3) c.121 A>G-p.(Met41Val) variant in \textit{UBA1} present in 96% of the reads (48/50 total reads). In light of the patient’s phenotype being discordant with known features of symptoms caused by germline \textit{UBA1} variants, but concordant with recently reported auto-inflammatory disease related to somatic \textit{UBA1} changes, additional testing was performed to elucidate the case. Postmortem research Sanger sequencing on archived tissue was able to confirm the absence of the p.(Met41Val) variant in a skin biopsy and in a gastric mucosa tissue sample both obtained pre-mortem (Fig. 1B). The absence of the variant in these tissues determined the variant as a postzygotic event. This confirmed the somatic nature of the p.(Met41Val) variant in the blood DNA, allowing for a definitive diagnosis, and appropriate genetic counseling and familial risk assessment.

Discussion and conclusion
Variants associated with VEXAS syndrome in p.(Met41) of \textit{UBA1} result in reduction of functional cytoplasmic UBA1 resulting in upregulated cellular stress responses and activation of multiple innate immune pathways (such as elevated interferon-γ, TNF, IL-6, IL-8) causing multiorgan involvement as the symptoms progress [6]. The mean age of VEXAS onset is 67 years, ranging from 47 to 79 years with fever being reported as one of the most common symptoms [2] [7]. Fever in our patient was present only at the beginning of his investigation when CAPS was suspected. In a cohort of 16 patients with VEXAS syndrome, macrocytic anemia was found in all, lymphopenia in twelve individuals, and myelodysplastic syndrome in six individuals [4]. The clinical manifestations exhibited in VEXAS syndrome are notably variable. However, recent cluster analysis has identified a potential phenotype-genotype correlation between the type of \textit{UBA1} variants and features exhibited [8]. The presented patient fits within the proposed phenotype of
Fig. 1  VEXAS syndrome skin lesions presented by the patient and Integrative Genome Viewer (IGV) and Sanger-sequencing electropherogram.  
A Edema and erythema with few subcutaneous indurated nodules in a linear, somewhat ropey pattern on right inner thigh.  
B Right dorsal hand is edematous and erythematous. Biopsy of the lesion showed subcutaneous panniculus with lipocyte necrosis, lipomembranous change, and clusters of neutrophils in the panniculus.  
C The UBA1 variant (NM_003334.3) c.121A>G: p.(Met41Val) is found in 96% of the reads in the blood. Sanger-sequencing in skin and stomach demonstrated the absence of the variant in these tissues.
**Table 1** Serum laboratory investigation

| Exam                              | Values | Reference range |
|-----------------------------------|--------|-----------------|
| Hemoglobin (g/dL)                 | 8.5    | 13.2–16.6       |
| Hematocrit (%)                    | 27.5   | 38.3–48.6       |
| Erythrocytes (× 10(12)/L)         | 2.01   | 4.35–5.65       |
| MCV (fL)                          | 136.8  | 78.2–97.9       |
| RBC distrib width (%)             | 18.8   | 11.8–14.5       |
| Platelet count (× 10(9)/L)        | 48     | 135–317         |
| White blood cell count (× 10(9)/L)| 8.5    | 3.4–9.6         |

**Inflammatory markers**

| C-reactive protein (MG/DL)        | 11.6   | 0.0–0.9         |
| Lactate dehydrogenase (U/L)      | 230    | 122–222         |
| Erythrocyte sedimentation rate (mm/hr) | 120   | 0–15            |

**Autoimmune**

| Soluble interleukin-2 receptor level (unit/mL) | 3017   | 45–1105         |
| dsDNA Ab with reflex, IgG, S (IU/mL)           | 20.6   | <30             |
| Antinuclear Ab, S (U)                          | 4.2    | ≤1.0            |
| Cyclic citrullinated peptide Ab, S (U)         | <15.6  | <15.0           |
| Centromere Ab, IgG, S (U)                      | <0.2   | <1.0            |
| SS-A/Ro Ab, IgG, S (U)                        | 7.9    | <1.0            |
| SS-B/La Ab, IgG, S (U)                        | <0.2   | <1.0            |
| Sm Ab, IgG, S (U)                              | <0.2   | <1.0            |
| RNP Ab, IgG, S (U)                             | <0.2   | <1.0            |
| ScI 70 Ab, IgG, S (U)                         | <0.2   | <1.0            |
| Jo 1 Ab, IgG, S (U)                           | <0.2   | <1.0            |
| Rheumatoid factor (IU/mL)                     | <15    | <15             |
| Ribosome P Ab, IgG, S (U)                     | <0.2   | <1.0            |
| Myeloperoxidase Ab, S (U)                     | <0.2   | <0.4            |
| Proteinase 3 Ab (PR3) (U):                    | <0.2   | <0.4            |

**Complement**

| Complement, total, S (U/mL)               | 69     | 30–75           |
| C1 esterase inhbl, functional, QN (%)     | >90    | >67             |
| Complement C1q, S (MG/DL)                 | 22     | 12–22           |
| Complement C4, S (MG/DL)                  | 24     | 14–40           |
| C1 esterase inhibitor antigen, S (MG/DL)  | 36     | 19–37           |
| Complement, total, S (U/mL)               | 69     | 30–75           |

**Immunoglobulins**

| Haptoglobin (MG/DL)                     | 228    | 30–200          |
| Immunoglobulin A (IgA) (MG/DL)          | 157    | 61–356          |
| Immunoglobulin E (IgE) (KU/L)           | 3.4    | ≤214            |
| Immunoglobulin G (IgG) (MG/DL)          | 976    | 767–1590        |
| Immunoglobulin M (IgM) (MG/DL)          | 47     | 37–286          |
| Immunoglobulin Subclass IgG4 (MG/DL)    | 9.3    | 24–121          |

**Miscellaneous**

| Carcinoembryonic Ag (CEA) (NG/ML)        | 1.2    |                 |
| Carbohydrate Ag 19–9, S (U/ML)**        | 1288   | <35             |
| Methylmalonic acid, quantitative (NMOL/ML) | 0.26  | ≤0.40           |
| PNH RBC-partial Ag loss (%)             | 0.0    | 0.00–0.99       |
| PNH RBC-complete Ag loss (%)            | 0.0    | 0.00–0.01       |

Abnormal results are shown in bold.

**The Ca19-9 was ordered to further evaluate pancreatic cysts found in his abdominal CT scan in the previous year. Whole body PET was normal.**

p.(Met41Val) with absence of chondritis, high CRP levels, and increased mortality risk.

VEXAS BM features are characterized by prominent cytoplasmic vacuoles in myeloid and erythroid cells. Even though these findings are not specific of VEXAS syndrome since they are present in other conditions such as myeloid neoplasms, copper deficiency, and alcohol intoxication, almost all of the confirmed cases in the literature have had this alteration [4, 9, 10]. Cytoplasmic vacuolation in hematopoietic cells was initially described for our patient but was not considered specific at the time, given it predated the clinical description of VEXAS syndrome by three years.

Many treatment-related complications have been described for patients with VEXAS syndrome including infections, cardiac involvement, stroke, and intestinal perforation indicating a poor prognosis with a mortality rate of 50% at the mean age of 76 [7, 11]. Our patient developed secondary complications such as cataracts, type 2 diabetes, and disseminated *Mycobacterium chelonae* infections, during the chronic use of corticosteroids. Sensorineural hearing loss was deemed associated with the use of amikacin, however this may have been due to VEXAS given it has been reported in 9% of the cases [2]. In one case series, no subject with VEXAS syndrome responded to disease-modifying anti-inflammatory drugs, while all were high-dose glucocorticoid-dependent [9]. Several immunosuppressive and immunomodulatory agents were used in our patient without adequate control. Stem-cell transplant has been proposed as potential treatment option and has shown preliminary favorable outcomes in case reports [10, 12–15]. A formal clinical trial evaluating allogeneic stem cell transplant in VEXAS is underway (ClinicalTrials.gov Identifier NCT05027945).

Germline variants in *UBA1* are associated with SMAX2 which is characterized by profound proximal hyponatremia with muscle biopsy findings of neurogenic atrophy with no clinical overlap with VEXAS syndrome [16]. Germline p.(Met41Val) variant is not yet described to be associated with SMAX2. Sanger technique has been described as the methodology of choice to identify somatic variants in *UBA1* in the peripheral blood. Important to note, low-level mosaicism (<20% of the cells) may be undetectable by Sanger sequencing so a next-generation technology with deeper coverage such as a targeted gene panel or ES might be warranted in some cases [3]. Interestingly, due to the high VAF, the *UBA1* pathogenic variant in our case was misinterpreted as being in a hemizygous state. High VAF has been described in the literature to occur in postzygotic event such as clonal hematopoiesis...
in variants in *TP53* with median VAF of 67.7% (range 46.9–84.7%) [17]. Regarding VEXAS, the highest value described in the literature was 83.35% in a patient diagnosed after analysis of peripheral-blood ES data [13]. Due to the absence of clinical features of SMAX2 in our patient, further testing in two different tissue samples through Sanger technique was used to confirm the somatic state of the *UBA1* variant. Testing to confirm the presence of somatic *UBA1* variant should be pursued, not only when the patient phenotype does not match that reported with SMAX2, but for patients with treatment-refractory inflammation with fever, cytopenia, cutaneous, and rheumatologic symptoms in general.

The present case exemplifies the diagnostic challenge that was imposed by the inaccurate recognition of the *UBA1* pathogenic variant as hemizygous on ES due to the VAF of the *UBA1* variant in the blood, which in this patient is the highest VAF recorded among VEXAS patients to date [3, 12]. It is important to consider sequencing different tissues when there is conflict between the *UBA1* variant status and the patient’s clinical presentation. Even though treatment for VEXAS syndrome is still challenging, early diagnosis can be life-changing since there are reports of favorable outcomes after allogeneic stem cell transplant.

**Abbreviations**

BM: Bone marrow; CAPS: Cryopyrin-associated periodic syndrome; ES: Exome sequencing; PAN: Polyarteritis nodosa; SMAX2: X-linked spinal muscular atrophy 2; VAF: Variant allele frequency; VEXAS syndrome: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s41927-022-00281-z.

**Additional file1 Table S1** Summary medication table outlining the patient’s medications used approximate durations and clinical response.

**Acknowledgements**

The authors would like to thank Dr. Jeannette Williams, Dr. Josh Christianson, Dr. Sarah Scott, Dr. Peter Grayson, Dr. Rebecca Belsom, and Dr. Susan English for their contribution in patient’s care. Additionally, the authors would like to thank patient’s wife for revising the manuscript and consenting for publication.

**Author contributions**

MVMBW, EM, and FPV analyzed and interpreted the patient data including interpretation of the genetics variants. MP analyzed and interpreted the patient data regarding the hematological disease being directly involved in the care of the patient. SKF analyzed and interpreted the patient data regarding the dermatologic disease, being directly involved in the care of the patient. MVMBW, EM, and FPV were involved in case discussion and assessment of the variants in other tissue samples confirming the diagnosis. All authors contributed to the study design, critically reviewed the first draft, approved the final version, and agreed to be accountable for the work. All authors have full access to the manuscript and all the data in the study.

**Funding**

There was no funding for the work associated with this publication. None of the authors have been paid by any agency or pharmaceutical company to write this article.

**Availability of data and materials**

The *UBA1* variant is a known pathogenic variant which is reported on ClinVar under accessions SCV001443136 and SCV002098354. If necessary, further information is available from the corresponding author on reasonable request. Further data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Declarations**

**Ethics approval and consent to participate**

The Mayo Clinic Institutional Review Board (IRB) acknowledges that based on the responses submitted for this new activity through the Mayo Clinic IRB Human Subjects Research Wizard tool, and in accordance with the Code of Federal Regulations, 45 CFR 46.102, the above noted activity does not require IRB review.

**Consent for publication**

The patient provided informed and written consent prior to his death to present and report his case. The wife’s patient as next of kin has graciously signed a written consent for the present publication.

**Competing interests**

None.

**Author details**

1. Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
2. Department of Clinical Genomics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
4. Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
5. Division of Dermatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
6. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
7. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.

**Received:** 29 January 2022  **Accepted:** 9 June 2022  **Published online:** 30 August 2022

**References**

1. The ubiquitin system: a critical regulator of innate immunity and pathogen–host interactions | Cellular & Molecular Immunology [Internet]. (cited 2021 Sep 9). Available from: https://www.nature.com/articles/cmci201640
2. Shaukat F, Hart M, Burns T, Bansal P. *UBA1* and *DNMT3A* Mutations in VEXAS Syndrome. A case report and literature review. *Mod Rheumatol* Case Rep. 2021;6(1):134–9.
3. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in *UBA1* and severe adult-onset autoinflammatory disease. *N Engl J Med.* 2020;383(27):2628–38.
4. Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in *UBA1*. *Blood Adv.* 2021;5(16):3203–15.
5. Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM, et al. Somatic mutations in *UBA1* define a distinct subset of relapsing polychondritis patients with VEXAS. *Arthritis Rheumatol.* 2021;73(10):1886–95.
6. Shaukat F, Hart M, Burns T, Bansal P. *UBA1* and *DNMT3A* mutations in VEXAS syndrome. A case report and literature review. *Mod Rheumatol* Case Rep. 2022;6(1):134–9.
7. Made CI van der, Potjewijd J, Hoogstins A, Willems HPI, Kwakernaak AJ, Sevaux RGL de, et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. Journal of Allergy and Clinical Immunology [Internet]. 2021 May 25 [cited 2021 Sep 9(0)]. Available from: https://www.jacionline.org/article/S0091-6749(21)00819-8/abstract

8. Georgin-Lavialle S, Terrier B, Guedon A, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. British Journal of Dermatology [Internet]. [cited 2022 Jan 25];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1111/bjd.20805

9. Huang H, Zhang W, Cai W, Liu J, Wang H, Qin T, et al. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder. Exp Hematol Oncol. 2021;10(1):23.

10. Koster MJ, Kourelis T, Reichard KK, Kermani TA, Beck DB, Cardona DO, et al. Clinical heterogeneity of the VEXAS Syndrome: A case series. In: Mayo Clinic Proceedings. 2021;S0025–6196(21)00481‑X.

11. Himmelmann A, Brücker R. The VEXAS Syndrome: uncontrolled inflammation and macrocytic anaemia in a 77-year-old male patient. Eur J Case Rep Intern Med. 2021;8(4):002484.

12. Staels F, Betrains A, Woei-A-Jin F, Boecx N, Beckers M, Bervoets A, et al. Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol. 2021;23(12):678927.

13. Koster MJ, Kourelis T, Reichard KK, Kermani TA, Beck DB, Cardona DO, et al. Clinical heterogeneity of the VEXAS syndrome: a case series. Mayo Clin Proc. 2021;96(10):2653–9.

14. Loschi M, Roux C, Sudaka I, Ferrero-Vacher C, Marceau-Renaut A, Duployez N, et al. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone Marrow Transpl. 2022;9:1–4.

15. Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a two center experience. Blood Advances [Internet]. 2021 Nov 2 [cited 2022 Jan 25]; Available from: https://www.sciencedirect.com/science/article/pii/S2473952921007709

16. Wang XH, Zhang LM, Yang X, Zhou SZ. A Pathogenic Missense variant (c.1617G>A, p. Met539Ile) in UBA1 causing infantile X-linked spinal muscular atrophy (SMAX2). Front Pediatr. 2020;8:64.

17. Deng J, Wu X, Ling Y, Liu X, Zheng X, Ye W, et al. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: a systematic review and meta-analysis. Eur J Haematol. 2020;105(5):524–39.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.